Biocon secures 10-year Pertuzumab supply deal in Brazil

Biocon secures 10-year Pertuzumab supply deal in Brazil. The 10-year contract marks a significant export win for the company in the Latin American market. Pertuzumab is a biosimilar drug used in cancer treatment, strengthening Biocon’s global footprint. This deal enhances revenue visibility for over a decade.

📊 STOCKS: $BIOCON | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma